CK-0803 is under clinical development by Cellenkos and currently in Phase I for Amyotrophic Lateral Sclerosis. According to GlobalData, Phase I drugs for Amyotrophic Lateral Sclerosis have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CK-0803’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CK-0803 overview

CK-0803 is under development for the treatment of amyotrophic lateral sclerosis, Parkinson's disease and chronic inflammatory demyelinating polyneuropathy (CIDP). The drug candidate comprises umbilical cord derived T regulatory cells. It is administered through intravenous route. It is being developed by CRANE technology.

Cellenkos overview

Cellenkos is a clinical biotechnology company that develops umbilical cord blood-derived T-regulatory cellular therapies for the treatment of autoimmune diseases and inflammatory disorders. Its pipeline products include CK0801, CK0802, CK0804, CK0803, CK0805, CK0806, CK0807 and CK0808. The company’s CK0801 leads to the replacement of defective T-REGs and protection of the body from T-cell attacks with the restoration of immune homeostasis. The company serves its services in the US. Cellenkos is headquartered in Houston, Texas, the US.

For a complete picture of CK-0803’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.